U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06927895) titled 'Breast Cancer Implementation Science Study With Educational Intervention' on April 04.
Brief Summary: A study uniquely focused on system-based practice change, measuring the impact of educational interventions on both patients and clinicians for the recognition and management of treatment-related adverse effects for HER2+/HER2 low breast cancer patients on or about to start on HER2 targeted antibody drug conjugates (fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine) and shared decision-making methodologies to improve adverse event (AE) management and patient-clinician communications.
Study Start Date: April, 2025
Study...